Form 4: Editas Medicine CFO Executes Automatic Tax-Related Sale

Editas Medicine CFO Amy Parison sold 464 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Summary

• CFO Amy Parison sold 464 shares of Editas Medicine common stock on June 3, 2026.
• The transaction was executed at a weighted average price of $2.701 per share.
• The sale was conducted under a Rule 10b5-1 automatic sales plan adopted on July 7, 2022.
• The transaction was non-discretionary, intended solely to cover tax withholding obligations following the vesting of restricted stock units on June 2, 2026.
• Following the transaction, the reporting person retains beneficial ownership of 14,970 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine, non-discretionary administrative action related to tax obligations.

Positives

• The sale was non-discretionary and pre-planned, indicating no change in management sentiment regarding the company's long-term prospects.

Negatives

• The transaction represents a reduction in the direct equity stake held by the Chief Financial Officer.

Risks

• The company remains subject to market volatility affecting its stock price, which currently trades at a low valuation level.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The sale does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard corporate governance practices for executives to manage tax liabilities upon equity vesting and do not typically signal a change in corporate strategy or insider confidence.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for biotech executives to avoid potential conflicts of interest regarding insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was small and non-discretionary.

Next Steps

• None mentioned.

Key Dates

Keywords

Editas Medicine, EDIT, Insider Trading, Form 4, Biotech, CFO